glsi-100
Generic: GP2 + GM-CSF·Code: GP2
glsi-100: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Development Pipeline (1)
| Company | Phase |
|---|---|
| Greenwich LifeSciences, Inc. (GLSI) | Phase 3 |
Clinical Trials (1)
A Randomized, Multicenter, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects With Residual Disease or High-Risk PCR After Both Neoadjuvant and Postoperative Adjuvant Trastuzumab-based Therapy (FLAMINGO-01)
Frequently asked questions
Who is developing glsi-100?
glsi-100 is being developed by Greenwich LifeSciences, Inc..
How many clinical trials involve glsi-100?
BioSniper tracks 1 clinical trial involving glsi-100.
Get deeper analysis on glsi-100
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
Start Free Analysis